Study design, rationale, and baseline characteristics: Evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (First) trial

Michael Davidson, Robert S. Rosenson, Kevin C. Maki, Stephen Nicholls, Christie M. Ballantyne, Carolyn Setze, Dawn M. Carlson, James Stolzenbach

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of oncedaily fenofibric acid or placebo on carotid intima-media thickness (CIMT) progression in patients with controlled lowdensity lipoprotein cholesterol (LDL-C) levels achieved through atorvastatin treatment, but with high TG and low HDL-C levels. Methods In this multicenter, double-blind study, 682 patients were randomized to once-daily delayed-release capsules of choline fenofibrate 135 mg (fenofibric acid [Trilipix®; Abbott, North Chicago, IL]) or placebo plus atorvastatin treatment after a 2- to 10-week diet and atorvastatin run-in period. Key inclusion criteria included age ≥45 years; posterior-wall common CIMT ≥0.7 mm on at least one side at baseline; fasting results of TG ≥150 mg/dL, and HDL-C ≤45 mg/dL for men or HDLC ≤55 mg/dL for women at screening while receiving atorvastatin; controlled LDL-C; and known coronary heart disease (CHD) or a CHD risk equivalent. The primary efficacy variable is the rate of change from baseline through week 104 in the mean posterior-wall intima-media thickness of the common carotid arteries (composite value of left and right sides). Conclusions This trial is the first to examine the effect of fenofibric acid on CIMT and the first CIMT trial to select patients with controlled LDL-C and elevated TG and low HDL-C as inclusion criteria. Also, this trial will prospectively evaluate the effect of treatment on LDL particles and address shortcomings of previous CIMT trials.

LanguageEnglish
Pages349-358
Number of pages10
JournalCardiovascular Drugs and Therapy
Volume26
Issue number4
DOIs
Publication statusPublished - 1 Aug 2012

Keywords

  • Atorvastatin
  • CIMT
  • Dyslipidemia
  • Fenofibric acid
  • LDL particle
  • Triglycerides

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Davidson, Michael ; Rosenson, Robert S. ; Maki, Kevin C. ; Nicholls, Stephen ; Ballantyne, Christie M. ; Setze, Carolyn ; Carlson, Dawn M. ; Stolzenbach, James. / Study design, rationale, and baseline characteristics : Evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (First) trial. In: Cardiovascular Drugs and Therapy. 2012 ; Vol. 26, No. 4. pp. 349-358.
@article{5ffa9ee1e2ae4adeb3a227876fa2cd42,
title = "Study design, rationale, and baseline characteristics: Evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (First) trial",
abstract = "Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of oncedaily fenofibric acid or placebo on carotid intima-media thickness (CIMT) progression in patients with controlled lowdensity lipoprotein cholesterol (LDL-C) levels achieved through atorvastatin treatment, but with high TG and low HDL-C levels. Methods In this multicenter, double-blind study, 682 patients were randomized to once-daily delayed-release capsules of choline fenofibrate 135 mg (fenofibric acid [Trilipix{\circledR}; Abbott, North Chicago, IL]) or placebo plus atorvastatin treatment after a 2- to 10-week diet and atorvastatin run-in period. Key inclusion criteria included age ≥45 years; posterior-wall common CIMT ≥0.7 mm on at least one side at baseline; fasting results of TG ≥150 mg/dL, and HDL-C ≤45 mg/dL for men or HDLC ≤55 mg/dL for women at screening while receiving atorvastatin; controlled LDL-C; and known coronary heart disease (CHD) or a CHD risk equivalent. The primary efficacy variable is the rate of change from baseline through week 104 in the mean posterior-wall intima-media thickness of the common carotid arteries (composite value of left and right sides). Conclusions This trial is the first to examine the effect of fenofibric acid on CIMT and the first CIMT trial to select patients with controlled LDL-C and elevated TG and low HDL-C as inclusion criteria. Also, this trial will prospectively evaluate the effect of treatment on LDL particles and address shortcomings of previous CIMT trials.",
keywords = "Atorvastatin, CIMT, Dyslipidemia, Fenofibric acid, LDL particle, Triglycerides",
author = "Michael Davidson and Rosenson, {Robert S.} and Maki, {Kevin C.} and Stephen Nicholls and Ballantyne, {Christie M.} and Carolyn Setze and Carlson, {Dawn M.} and James Stolzenbach",
year = "2012",
month = "8",
day = "1",
doi = "10.1007/s10557-012-6395-z",
language = "English",
volume = "26",
pages = "349--358",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "Kluwer Academic Publishers",
number = "4",

}

Study design, rationale, and baseline characteristics : Evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (First) trial. / Davidson, Michael; Rosenson, Robert S.; Maki, Kevin C.; Nicholls, Stephen; Ballantyne, Christie M.; Setze, Carolyn; Carlson, Dawn M.; Stolzenbach, James.

In: Cardiovascular Drugs and Therapy, Vol. 26, No. 4, 01.08.2012, p. 349-358.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Study design, rationale, and baseline characteristics

T2 - Cardiovascular Drugs and Therapy

AU - Davidson, Michael

AU - Rosenson, Robert S.

AU - Maki, Kevin C.

AU - Nicholls, Stephen

AU - Ballantyne, Christie M.

AU - Setze, Carolyn

AU - Carlson, Dawn M.

AU - Stolzenbach, James

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of oncedaily fenofibric acid or placebo on carotid intima-media thickness (CIMT) progression in patients with controlled lowdensity lipoprotein cholesterol (LDL-C) levels achieved through atorvastatin treatment, but with high TG and low HDL-C levels. Methods In this multicenter, double-blind study, 682 patients were randomized to once-daily delayed-release capsules of choline fenofibrate 135 mg (fenofibric acid [Trilipix®; Abbott, North Chicago, IL]) or placebo plus atorvastatin treatment after a 2- to 10-week diet and atorvastatin run-in period. Key inclusion criteria included age ≥45 years; posterior-wall common CIMT ≥0.7 mm on at least one side at baseline; fasting results of TG ≥150 mg/dL, and HDL-C ≤45 mg/dL for men or HDLC ≤55 mg/dL for women at screening while receiving atorvastatin; controlled LDL-C; and known coronary heart disease (CHD) or a CHD risk equivalent. The primary efficacy variable is the rate of change from baseline through week 104 in the mean posterior-wall intima-media thickness of the common carotid arteries (composite value of left and right sides). Conclusions This trial is the first to examine the effect of fenofibric acid on CIMT and the first CIMT trial to select patients with controlled LDL-C and elevated TG and low HDL-C as inclusion criteria. Also, this trial will prospectively evaluate the effect of treatment on LDL particles and address shortcomings of previous CIMT trials.

AB - Purpose Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of oncedaily fenofibric acid or placebo on carotid intima-media thickness (CIMT) progression in patients with controlled lowdensity lipoprotein cholesterol (LDL-C) levels achieved through atorvastatin treatment, but with high TG and low HDL-C levels. Methods In this multicenter, double-blind study, 682 patients were randomized to once-daily delayed-release capsules of choline fenofibrate 135 mg (fenofibric acid [Trilipix®; Abbott, North Chicago, IL]) or placebo plus atorvastatin treatment after a 2- to 10-week diet and atorvastatin run-in period. Key inclusion criteria included age ≥45 years; posterior-wall common CIMT ≥0.7 mm on at least one side at baseline; fasting results of TG ≥150 mg/dL, and HDL-C ≤45 mg/dL for men or HDLC ≤55 mg/dL for women at screening while receiving atorvastatin; controlled LDL-C; and known coronary heart disease (CHD) or a CHD risk equivalent. The primary efficacy variable is the rate of change from baseline through week 104 in the mean posterior-wall intima-media thickness of the common carotid arteries (composite value of left and right sides). Conclusions This trial is the first to examine the effect of fenofibric acid on CIMT and the first CIMT trial to select patients with controlled LDL-C and elevated TG and low HDL-C as inclusion criteria. Also, this trial will prospectively evaluate the effect of treatment on LDL particles and address shortcomings of previous CIMT trials.

KW - Atorvastatin

KW - CIMT

KW - Dyslipidemia

KW - Fenofibric acid

KW - LDL particle

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=84864460998&partnerID=8YFLogxK

U2 - 10.1007/s10557-012-6395-z

DO - 10.1007/s10557-012-6395-z

M3 - Article

VL - 26

SP - 349

EP - 358

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 4

ER -